FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...
A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...
March 9 (Reuters) - Bristol Myers Squibb on Monday said its experimental cancer drug met the main goal of a late-stage study.
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news ...
Surgeon Gareth Honeybone wants wider access to zanidatamab to treat one of the deadliest cancers.
Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated ...
News-Medical.Net on MSN
Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Roche said the late-stage trial did not provide reliable evidence that the drug's use in combination with Pfizer's Ibrance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results